Editas Medicine (EDIT), a biotech focused on developing treatments using the gene-editing technology CRISPR, said Tuesday that its president and chief executive, Katrine Bosley, would resign her roles effective March 1. She will also resign her role as a company director. Board member Cynthia Collins, the former chief executive of Human Longevity, will serve as interim chief executive while Editas searches for a replacement.
Shares in Editas were down 22 percent to $20.41 in morning trading.
